Trials / Unknown
UnknownNCT03771079
MS Detection of Somatic Mutations in Hematological Malignancies
Evaluation of MassArray Platform Versus Illumina Miseq for the Detection of Driver Mutations in Hematological Malignancies
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limitation for its availability. An original approach is now available, using mass spectrometry (MS). In this study the analytical performance of both methods will be compared, using samples that were previously analyzed by NGS. The goal of the study is to assess whether MS can represent or not a faster and cheaper way to detect key point mutations in patients suffering from hematological malignancies
Conditions
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2018-12-10
- Last updated
- 2018-12-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03771079. Inclusion in this directory is not an endorsement.